APP and amyloidosis: Pharmacologic miR‐425 replacement targeting the normalization of APAM gene networks is possible, as we find that miR‐425 supplementation reverses the changes of target genes associated with disease and attenuates amyloid plaque formation in APP/PS1 mice.